Response of human liver tissue to innate immune stimuli

Xia Wu^{1,*}, Jessica B. Roberto¹, Allison Knupp¹, Alexander L. Greninger^{1,3}, Camtu D. Truong¹,
Nicole Hollingshead¹, Heidi L. Kenerson², Marianne Tuefferd⁴, Antony Chen⁴, Helen Horton⁴,
Keith R. Jerome^{1,3}, Stephen J. Polyak¹, Raymond S. Yeung² and Ian N. Crispe¹

¹Department of Laboratory Medicine and Pathology, and ²Department of Surgery, University of
Washington, Seattle, WA, USA 98195

³Fred Hutchinson Cancer Research Institute, Seattle, Washington, USA.

⁴Infectious Diseases and Vaccines, Janssen Research and Development, B-2340 Beerse,
Belgium.

*To whom correspondence should be addressed:

Xia Wu, Ph.D.

Department of Medicine, University of Washington,

750 Republican St., E630, Seattle, WA 98109

E-mail: xiawu2@uw.edu Tel: 1-206-221-3343

Keywords: liver slice culture, innate immunity, Hepatitis C virus, direct-acting antiviral
treatment, inflammation, fibrosis

24 **Short Title:** innate immune response with PCLS

25

26 **Number of figures and tables**

27 6 figures, 1 table

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

Conflict of Interest statement

The authors declare no relevant conflicts of interest.

Financial support

This work was supported by NIH NIAID R56 grant AI143683; US Department of Defense grant CA150370; Janssen Research and Development; the Seattle Foundation; and the University of Washington.

Acknowledgements

We thank Pathology Research Services Laboratory, and Histology and Imaging Core (HIC) at UW for their help in data and image acquisition.

Authors' contributions

X.W., J.B.R., A.C., H.H., R.S.Y. and I.N.C. designed research; X.W., J.B.R., A.K., A.L.G., N.H., H.L.K, M.T. and A.C. performed research; K.R.J., S.J.P. and R.S.Y. contributed reagents/analytic tools; X.W., A.L.G., C.D.T. and I.N.C. analyzed data; X.W., S.J.P. and I.N.C. wrote the manuscript; all authors reviewed the manuscript and provided suggestions.

70 **Abbreviations**

71 Abbreviations are provided for some terms not commonly known; some are also explained in the
72 manuscript. Authors will conform with journal standards if paper is accepted scientifically.

73

74	PCLS	precision-cut liver slice
75	TLR	toll-like receptor
76	NPC	non-parenchymal cell
77	KC	Kupffer cells
78	LSEC	Liver sinusoidal endothelial cells
79	HSC	hepatic stellate cells
80	HCV	hepatitis C virus
81	DAA	direct-acting antiviral
82	ISGs	interferon-stimulated genes
83	HCC	hepatocellular carcinoma
84	ICC	intrahepatic cholangiocarcinoma
85	SVR	sustained virologic response

86

87

88

89

90

91

92

Abstract

Precision-cut human liver slice cultures (PCLS) has become an important alternative immunological platform in preclinical testing. To further evaluate the capacity of PCLS, we investigated the innate immune response to TLR3 agonist (poly-I:C) and TLR4 agonist (LPS) with the normal and pathological liver tissue. Pathological liver tissue was obtained from patients with active chronic HCV infection, and patients with former chronic HCV infection cured by recent Direct-Acting Antiviral (DAA) drug therapy. We found that hepatic innate immunity was not suppressed but enhanced in the HCV-infected tissue, compared with the healthy controls. Furthermore, despite recent HCV elimination, DAA-cured liver tissue manifested ongoing abnormalities in liver immunity. Sustained abnormal immune gene expression in DAA-cured samples were identified from direct *ex vivo* measurements and with TLR3 and TLR4 stimulation assays. Those genes that were up-regulated in chronic HCV-infected liver tissue were enriched in expression in the liver non-parenchymal cell compartment. These results demonstrated the utility of PCLS in studying the liver pathology and innate immunity.

Introduction

We recently reported the development of human liver slice technology (PCLS) as an immunological platform^{1,2}. Compared with other liver research methods, the PCLS method has the advantage that hepatocytes and the major subsets of non-parenchymal cells (KC, LSEC and HSC) are cultured together in their normal anatomical relationships, enabling the analysis of liver cell function in the context of intercellular interaction. Furthermore, the patterns of liver disease that are present in fresh tissue could be maintained over time in the slice cultures¹. For example, steatotic liver slices retains fat droplets, and cholestatic liver slices were manifested with yellow-green pigment in hepatocytes. However, it remained unclear whether PCLS has the capacity to reveal the dynamic alternations in innate immune response that may occur in pathological liver tissue compared with healthy controls. As a proof of principle, we compared the dynamic response with PCLS with liver tissue collected from three groups of patients which included non-infected subjects, chronic HCV-infected patients, and patients whose HCV was cured by DAA treatment.

HCV-infected liver tissue is of particular interest, because HCV infection is one of the most common liver diseases in the USA and globally. Approximately 71 million individuals are infected with HCV worldwide³. The acute phase of infection is often subclinical, but 55–85% of infected individuals develop a chronic infection leading to progressive liver pathology⁴. The World Health Organization (WHO) estimated that approximately 399,000 people died from HCV-related diseases in 2016, mostly from cirrhosis and hepatocellular carcinoma (HCC).

The recent introduction of highly effective direct-acting antiviral (DAA) drugs has presented a unique opportunity to investigate the resolution of pathological liver to normality after HCV elimination. The extent to which such drugs revert the liver to normal is not fully resolved, with some studies suggesting that HCV clearance with DAA therapy leaves residual abnormalities in innate immunity in peripheral monocytes and NK cells ^{5,6}, adaptive immunity in peripheral CD4⁺ and CD8⁺ T cells ⁷⁻¹⁰, in $\gamma\delta$ -T cells ¹¹, in mucosal associated invariant T cells ¹², and in the persisting risk to hepatocellular cancer ¹³⁻¹⁶. Other studies also found abnormal serum lipids ¹⁷, persistent epigenetic modifications ^{18,19}, and sustained hepatic inflammation ²⁰ in liver biopsies after DAA treatment. To our knowledge, no studies have evaluated hepatic immunity of untreated versus DAA-treated HCV infection in the context of intact liver tissue.

Materials and Methods

Liver samples, preparation and culturing

Fresh non-tumor liver tissues were obtained from patients undergoing liver resection at the University of Washington Medical Center (Seattle, WA, USA). All patients in this study prospectively consented to donate liver tissue for research under the Institutional Review Board protocol #00001852. Tissue from DAA-treated patients were collected from those who achieved sustained virologic response (SVR), with HCV viral load being non-detected after the completion of DAA therapy. Clinical details of these patients are provided in **Table S1**.

Liver slicing and culturing were as previously described¹. Briefly, liver cores of 6 mm diameter were excised from the resected liver tissue using a biopsy punch (Integra Miltex, York, PA, USA), stored in BELZER-UW solution (Bridge to Life Ltd., Columbia, SC, USA), and transferred to the research laboratories typically within 1 h of tissue excision. Slices 250 µm thick were prepared using a vibrating microtome, Leica VT1200 S (Nussloch, Germany), using Dulbecco's Modified Eagles Medium (DMEM) as the cutting medium. Liver slices were cultured individually on 0.4 µm millicell organotypic inserts in 24 well plates (Millipore Corporation, Billerica, MA, USA). The culturing medium comprised 1 × advanced-DMEM medium, 5% Fetal Bovine Serum (FBS), 1 × GlutaMAX, 0.5 × Penicillin-Streptomycin, 1 × Insulin-Transferrin-Selenium supplement and 15 mM HEPES (pH 7.2 - 7.5) (all from Gibco, Grand Island, NY, USA). The liver cultures were maintained on a rocking platform at 17 rpm in a humidified incubator at 5% CO₂ and atmospheric concentration of O₂ at 37°C. The medium was renewed every two to three days.

Histology of liver slices

Liver slices were fixed with the 10% neutral-buffered formalin at room temperature for 24 h. The fixed liver slices were embedded in paraffin and were sliced into 4 µm-thick sections. Trichrome stain, picosirius red stain, and hematoxylin and eosin (H&E) stain were analyzed with the standard protocol in the Pathology Research Services Laboratory at Department of Laboratory Medicine and Pathology at UW. The fibrosis score of liver slices was analyzed by a pathologist blinded from the patient clinical diseases. The Scheuer/Batts-Ludwig method was used for fibrosis scoring, with 0: No fibrosis, 1: portal fibrosis, 2: peri-portal fibrosis, 3: bridging

fibrosis, and 4: cirrhosis. The whole-slide images were recorded with Nanozoomer Whole Slide Scanner (Hamamatsu City, Shizuoka Pref., Japan) and visualized with NDP.view2 software (Hamamatsu).

Liver perfusion and isolation of liver cells

Human liver cell isolation procedures were adapted from several sources^{21,22}. Cell isolation was performed on wedges of resected tissue rather than cores. Perfusion buffer contained 1 × Hank's Balanced Salt Solution (HBSS, without Ca⁺⁺, Mg⁺⁺, or phenol red, from Gibco), 10 mM HEPES (pH 7.2-7.5) and 0.5 mM EDTA (pH 8.0). Collagenase buffer contained 1 × HBSS (Gibco), 5 mM MgCl₂, 5 mM CaCl₂, 5 mM HEPES (pH 7.2-7.5), 0.5% w/v Collagenase IV (Sigma-Aldrich, St. Louis, MO, USA), 0.25% w/v Protease (Sigma), 0.125% w/v Hyaluronidase (Sigma), 0.05% w/v DNase I (Sigma). Fresh aliquots of enzymes were added to the buffer on the day of the perfusion experiment. Forty mL of Perfusion buffer and 20 mL of Collagenase buffer were used for each 10 g of liver tissue. Buffers were pre-warmed to 37°C prior to the perfusion step.

Liver tissue wedges were sequentially perfused with Washing buffer (1 × HBSS and 10 mM HEPES, pH 7.2-7.5), Perfusion buffer, Washing buffer, and the recirculating Collagenase buffer at a flow rate of 12 mL/min (Gilson's MINIPULS 3, Middleton, WI, USA). The perfused liver tissue samples were gently mashed with a sterile syringe plunger through a sterile mesh strainer in ice-cold DMEM medium. Cell extracts were filtered through a 100 µm sterile strainer and centrifuged at 50 × g at 4°C for 3 min to enrich for hepatocytes in the pellets and non-

parenchymal cells in the supernatant. The supernatants were transferred to a new tube and kept on ice. The pellets were washed three times with ice-cold DMEM medium, and were pelleted each time at $50 \times g$ at 4°C for 3 min. To further improve the purity of the isolated hepatocytes, cell pellets were resuspended with 5 mL of ice-cold PBS, overlaid with 10 mL of 25% Percoll gradient solution. The mixture was centrifuged at $1400 \times g$ (no brake) at 4°C for 20 min. The pellet contained the purified live hepatocytes. The viability of the isolated hepatocytes was determined with the trypan blue exclusion assay (Thermo Fisher Scientific, Waltham, MA, USA). If the viability was greater than 50%, the isolated hepatocytes were stored for RNA extraction.

For the non-parenchymal cells (NPC), the $50 \times g$ centrifuge supernatants were further centrifuged at $500 \times g$ at 4°C for 7 min. The pellets were resuspended in 5 mL of ice-cold PBS, and overlaid on top with 50% and 25% Percoll gradients (10 mL layers each), and were centrifuged at $1400 \times g$ (no brake) at 4°C for 20 min. Cell layers were collected into 20 mL PBS each, and centrifuged again at $500 \times g$ at 4°C for 7 min. A fraction of the pellets were saved for RNA extraction, which were the total NPC. The rest of the pellets were resuspended with the ice-cold Flow buffer containing $1 \times \text{PBS}$, 2% FBS, and 1 mM EDTA. Experimental Overview is illustrated in Fig. S1.

Flow cytometry and cell sorting

The isolated non-parenchymal cells were stained with an antibody mixture that included eBioscience (San Diego, CA, USA): anti-CD45 (Cat. No. 15-0459-42); BioLegend (San Diego,

CA, USA): anti-CD3 (Cat. No. 317330), anti-CD11b (Cat. No. 553310), anti-CD14 (Cat. No. 301834), anti-CD31 (Cat. No. 303120), anti-CD32 (Cat. No. 303206), anti-CD68 (Cat. No. 333814), and anti-CD271 (Cat. No. 345110). In addition, cells were also stained with LIVE/DEAD Fixable Far Red Dead Cell Stain Kit (Cat. No. L10120, Life Technologies, Carlsbad, CA, USA). The incubation mixture was kept at 4°C for 30 min in the dark on a rocking platform. The mixture was centrifuged with $500 \times g$ at 4°C for 7 min. Cells were washed once with Flow buffer.

The antibody-labeled cells were sorted with a BD Aria III (BD Biosciences, San Jose, CA, USA). Analysis of cell populations was performed using FlowJo software, version 9.8.5 (FlowJo, LLC, Ashland, OR, USA). Kupffer cells were selected as the CD45⁺, CD3⁻, CD14⁺, CD68⁺, CD32⁺ populations^{23,24}. LSECs were selected as CD45⁻, CD31⁺, CD11b⁻²⁵. HSCs were selected as CD45⁻, CD271⁺, autofluorescence positive with the emission wavelength at 460 nm, SSC-H > 150 units^{26,27} (**Fig. S1**). Cells were pelleted at $500 \times g$ at 4°C for 7 min, and were stored in -80°C before RNA extraction.

RNA isolation and qRT-PCR analysis

The RNA of liver slices or the purified liver cells was isolated with TRIzol and the Direct-zol RNA MiniPrep Kit (Zymo Research, Irvine, CA, USA). The RNA concentration was measured with nanoDrop (Thermo Fisher Scientific). The cDNA was synthesized with the QuantiTect Reverse Transcription Kit (Qiagen, Hilden, Germany).

A pre-amplification was performed before the multiplex qRT-PCR assays to improve the detection sensitivity^{28,29}, which included PCR reactions of cDNA as templates, and the 0.2 fold-diluted primer mixture of TaqMan assays of interest (Thermo Fisher Scientific) and the BIO-X-ACT Short Mix reagents (Bioline USA Inc., Taunton, MA, USA). The pre-amplified samples were diluted five-fold with RNase- and DNase-free H₂O. Samples were analyzed with a 48 × 48 dynamic array and a BioMark HD microfluidics system (Fluidigm, San Francisco, CA, USA). The Fluidigm Real-Time PCR Analysis software was used to calculate Ct thresholds, using the settings of quality threshold 0.65, baseline correction linear, Ct threshold method auto detection. Gene abundance of individual liver slices was normalized to the arithmetic mean of Ct values of ACTB, HPRT, and GAPDH. Typically, three liver slices were analyzed for each subject for each time point. The arithmetic mean delta Ct of three liver slices was used to in the figures and for statistical analysis. The hierarchical clustering was analyzed with Cluster 3.0³⁰. Heat map was visualized with Java Treeview (version 1.1.6r4)³¹.

HCV RNA measurement

HCV RNA was measured with a Food and Drug Administration-approved Abbott Real-Time HCV assay (Abbott Molecular, Des Plaines, IL, USA) as previously described^{20,32}. Fifty ng of total RNA for each sample was input in the assay, and HCV IU/ng total RNA was calculated from the calibration curve of positive controls. The reliable detection limit for HCV with this assay was 1.2 IU/ 50 ng liver total RNA.

Validation of liver cell types with cell-type-specific genes

277

278 Liver cell-type-specific genes for hepatocytes, Kupffer cells (KC), liver sinusoidal endothelial
279 cells (LSEC) and hepatic stellate cells (HSC) were obtained from previous microarray analysis
280 of liver FACS purified cells ¹ and recent publications of liver single cell RNAseq ^{33,34}.
281 Enrichment of the FACS purified liver cell types were confirmed by the selective expression of
282 cell-type-specific genes.

283

284 ***Ex vivo* stimulation of liver slices with poly-I:C and LPS**

285

286 Liver slices were cultured *ex vivo* for 7 days. Final concentrations of 15 µg/mL polyinosinic–
287 polycytidylic acid (poly-I:C) (Sigma, Cat. No. P1530), 1.5 µg/mL lipopolysaccharide endotoxin
288 (LPS) (Sigma, Cat. No. L2630) or 1 × PBS (control, matched by volume) were added to the
289 growth medium. During the stimulation, liver slices were maintained on transwell inserts placed
290 on a rocking platform at 37°C. Three liver slices were harvested at each time point, including 0
291 h (time zero control), 2 h, 4 h, 8 h, 12 h or 24 h. The concentrations of poly-I:C and LPS
292 treatments were based on our previous studies with isolated liver leukocytes ³⁵ and liver slices ¹.

293

294 **Statistical significance test**

295

296 The non-parametric Mann Whitney test, Kruskal-Wallis test with Dunn's post test with multiple
297 test comparison correction, and Wilcoxon matched-pairs signed rank test were performed using
298 Prism (version 9.1.0) (GraphPad Software Inc., CA, USA). Multiple comparison correction was
299 not applied in the gene expression analysis, because a specific set of genes were targeted for

analysis unlike the standard procedure in a data-driven functional genomics study. In this circumstance, correction for type I error is not advised, because the correction could lead to inflation of type II error (i.e. false negatives)³⁶. The issue of type II errors also arises because of the limited number of tissue samples available to us. For these reasons, we treated each gene we selected as an individual measurement.

Results

As a first step, we verified the robust response of liver slices during poly-I:C and LPS exposure (**Fig. 1, S2**). The added 2 h time point confirmed that *IFN-α*, *IFN-β*, *IFN-γ* and *IFN-λ* was stimulated prior to the elevation of interferon-stimulated genes *IFIT1/2*, *MX1*, *CXCL10* and *RSAD2* by poly-I:C. The induction of these antiviral genes was greater with poly-I:C compared with LPS induction (**Fig. 1, S2**). In contrast, *IL1B* and *IL6* were more robustly stimulated by LPS. The response of *IL1B* and *IL6* extended to 24 h post stimulation; in comparison, TNF peaked at 2 h, and gradually declined at 4, 8, 12, 24 h post-stimulation time points (**Fig. S2**). The temporal and gene specificity in poly-I:C and LPS response provided the basis for further dynamic testing of HCV-infected and DAA-cured liver tissue.

Detection and quantitation of HCV RNA with liver slices

Liver tissue from eight chronic HCV-infected patients were studied. All eight patients were diagnosed with primary liver cancer, either hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC). Four HCV genotypes were identified including HCV G1a, G1b, G2, G6. Likewise, liver tissue from ten DAA-cured patients were studied. The DAA-cured patients completed 8-24 weeks of DAA therapy. All subjects achieve sustained virologic response (SVR) with HCV RNA below the limit of detection after completion of DAA treatment. However, these DAA-cured patients were diagnosed with primary liver cancer (HCC or ICC) post DAA therapy. The time from completion of DAA treatment to liver resection surgery (i.e. the time liver tissue was collected) ranged from less than 1 month to 20 months, with a median of 9 month post-DAA therapy completion (**Table S1**).

To assure the identity of HCV infection, HCV copies and genotype were analyzed by UW virology clinic using the FDA-approved HCV assays. Liver slices originated from the chronic HCV patients were all confirmed with detectable HCV RNA, ranged from 1.2 to 9760.1 with the median value 3325.4 IU/50 ng total RNA. In comparison, none of the non-infected or DAA-treated subjects were positive for HCV RNA *ex vivo* based on the limit of detection of 1.2 IU/50 ng total RNA (**Fig. 2A**). Moreover, chronic HCV-infected liver slices continued to be HCV positive after 7 days of *ex vivo* culture (**Fig. 2B**), with a range of 1.8-14365.8, and median 405 IU/50 ng total RNA. The viral load on day 7 did not significantly differ from day 0 (Wilcoxon matched-pairs signed rank test, two-tailed, $P=0.4688$). Previous study showed that HCV can replicate in human liver slices culture for more than 10 days ³⁷.

Fibrosis in chronic HCV-infected and DAA-cured liver tissue

Because chronic HCV infection induced liver cirrhosis, we examined the liver tissue for fibrosis using picrosirius red and Masson's trichrome staining (**Fig. 2C**). Previous indirect measurements with transient elastography and noninvasive fibrosis indices reported regression of liver fibrosis after DAA treatment^{38,39}. Nevertheless, direct analysis of the liver tissue revealed that six out of eight DAA-cured patients met the definition of cirrhosis (i.e. fibrosis score of 4, Scheuer/Batts-Ludwig method) in livers despite the absence of HCV RNA, even after 20 months after DAA therapy (**Fig. 2C, Fig.3**). Likewise, the untreated chronic HCV livers were fibrotic as expected⁴⁰. None of the non-infected subjects had advanced liver fibrosis. Since the duration between the liver tissue collection and the time point of SVR ranged from less than 1 month to 20 months, it remains plausible that the fibrosis will be slowly resolved over a greater time span. As a result of the fibrotic status in HCV-infected and DAA-cured liver tissue, and that HCV-free fibrotic liver tissue was not available in this study, an important caveat is that the abnormal immune gene expression in both the HCV-infected and the DAA-cured liver slices could result either directly from HCV infection, or as a consequence of the fibrosis. .

Immune gene abnormality in chronic HCV-infected and DAA-cured *ex vivo*

We used multiplex qRT-PCR to examine 140 genes functioning in immune activation and suppression, and tissue repair. Forty immune genes differed in expression in chronic HCV-infected livers versus non-infected patients (Mann Whitney test, two-tailed, $P < 0.05$) (**Fig. 4A**). This included antiviral interferon (IFN)-stimulated genes (ISGs) including *IFIT1/2/3*, *ISG15*,

RSAD2, *MXI*, *CXCL9*, *CXCL10*, consistent with previous reports ⁴¹⁻⁴⁴. In addition, immune activation genes including MHC genes *HLA-A*, *HLA-DRA*, *CIITA*, *CD80*, *CD86*, tumor necrosis factor (TNF) superfamily genes *OX40*, *4-1BB*, *TNFSF9*, *TNFRSF18* and inflammation genes including *CASP1*, *IL-12A*, *IL-12B*, *TNF*, *IL-18*, and *NFKB* were also significantly up-regulated in HCV-infected livers (**Fig. 4A**).

DAA treatment restored the antiviral genes to baseline, as reported previously ⁴⁵, but some immune genes were remained elevated after cure of HCV infection. These included immune activation genes (*HLA-A*, *CIITA*, *4-1BB*, *CCL5*, *CCR2*), inflammatory genes (*CASP1*, *IL-12A*), and immune suppression genes (*CTLA4*, *TIGIT*, *IDO1*, *ARG1*). (**Figs. 4A**)

The phosphoinositol-3-kinase (PI3K) pathway-linked genes are susceptible to modification by HCV infection ¹⁸ and liver fibrosis ^{46,47}. We found that *SPHK1*, *BTG2*, *SOX9*, *SNAP25*, and *GPRC5B* were significantly up-regulated in chronic HCV infected livers. Furthermore, *SPHK1*, *BTG2*, and *SOX9* remained significantly up-regulated after HCV clearance with DAA treatment (**Fig. 4A**).

Immune gene subsets mapped to hepatic non-parenchymal immune cells

To identify the cellular origin of the dysregulated immune gene subsets, we investigated gene expression with liver specific cells purified from FACS ¹. Six liver wedge samples of non-infected liver tissue were large enough in size and anatomically ideal for perfusion through the

vasculature, which allowed them to be dissociated and analyzed for gene expression. We could not do this with samples of DAA-cured patients due to limitations in the amount of liver tissue obtained. Liver cell types were confirmed with respective cell expression markers^{1,33,48}, including *FCN1*, *NLRP3*, *ITGA4* for KC, *EMCN*, *VWF*, *CD34* for LSEC, *FGFR2*, *PDGFRB*, *COL1A1*, *LRAT* for HSC, and *FBP1*, *RBP4*, *ALB* for hepatocytes (**Fig. S3**). Many immune genes that were up-regulated in HCV-infected or DAA-cured fibrotic liver tissue were significantly enriched in the Non-Parenchymal Cell (NPC) compartment (**Table 1, Figs. 4B**). For a smaller subset of immune genes, we were able to map them to specific immune cells with greatest expression, for example *CIITA* mapped to Kupffer cells (KC), *HLA-A* and *CX3CL1* mapped to liver sinusoidal endothelial cells (LSEC), and *IL-12B* mapped to Hepatic Stellate Cells (HSC) (**Fig. 4B, Fig. S4**). Even though NPC may not include the cell types targeted by HCV infection, previous studies demonstrate that NPC can be activated through paracrine signaling from the neighboring HCV-infected hepatocytes^{43,49,50}.

Innate immune responses were altered in HCV infected and DAA-cured liver tissue

We stimulated liver slices with poly-I:C and LPS for varying times using the method established in our previous study¹. We chose day 7 as the time to add stimuli because the immune genes activated by tissue slicing had broadly stabilized after 4 days of *ex vivo* culture¹. The immune genes were recorded at the day 7 baseline prior to the treatment. A number of the immune genes remained at elevated baseline in HCV-infected or DAA-cured samples compared with non-infected control (**Fig. 4AB**). The PBS mock stimulation did not significantly induce IFNs and ISGs in liver slices¹. Notably, expression of TLR3, TLR4 themselves and NF- κ B transcription

factor were not significantly different at day 7 among chronic HCV-infected, DAA-treated and non-infected liver slices (**Fig. S5A**). We used the ΔC_t method with internal normalization to *ACTB*, *GAPDH* and *HPRT* to evaluate the overall abundance level post stimulation (**Fig. S6**). We also used the $\Delta\Delta C_t$ method against the day 7 T_0 to assess the enhanced net increase of genes during TLR3/TLR4 response (**Fig. 5**). We confirmed that TLR3 and TLR4 are primarily expressed in the NPC compartment (**Fig. S5B**).

First, robust induction of IFNs and ISGs by both TLR3 and TLR4 agonists was observed in liver slices from all three groups of liver specimens (*i.e.*, non-infected, HCV-infected, and DAA-cured). The sequential signaling cascade induced by TLR3 and TLR4 pathways described in **Fig.1** and **Fig. S1** for non-infected liver tissue, were also pronounced in the HCV-infected and DAA-cured liver tissue. For example, *IFNB1* and *IFNL3* (IL28B) peaked at 2-4 h, prior to the maximum abundance of ISGs (*IFIT 1/2/3*, *RSAD2* and *MX1*) which occurred at 4-8 (**Figs. 5 and S6**).

Second, some immune genes were not suppressed but induced more strongly by TLR3 agonist in liver slices of chronic HCV-infected liver at least at one time point (Mann-Whitney test, two tailed, $P < 0.05$). These included antiviral genes *MX1*, *RSAD2*, *IFNG*, chemokine genes *CCL3*, *CX3CL1*, *CXCL9*, inflammatory genes *TNF*, *CASP1* and *IL-10* (**Fig. S7**). Other common activation markers for TLR3 signaling, including *IFNB1*, *IL28B*, *IFIT 1/2/3*, *ISG15*, *CXCL10*, *IL-1B* and *CCL-5*, were also responsive in chronic HCV-infected slices with elevation of greater than 10-fold, as strong as changes in the non-infected liver slices. Thus, TLR3 sensing and signaling did not appear to be impaired in chronic HCV-infected liver slices. Furthermore, *TNF*,

IL-10 and *RSAD2* remained abnormally induced at 12 h and 24 h in chronic HCV liver slices, indicating persistent inflammation.

TLR4 sensing and signaling were similarly robust in chronic HCV-infected livers. *IFIT1*, *IFIT3*, *RSAD2*, *MX1*, *CCL3*, *CASP1* and *IL-10* were again identified along with *IL-8*, *IL-1B*, *IL-1A* and *IL12B* at greater abundance post LPS stimulation in chronic HCV-infected liver slices on at least one time point (Mann-Whitney test, two tailed, $P < 0.05$) (**Fig 6A**).

Third, most of the hyper-induction of the genes in HCV-infected tissue (9/11 genes in TLR3 response, 12/18 genes in TLR4 response) was not reversed in the tissue from formerly HCV+, but now successfully treated donors. *IFIT2*, *IFNB1*, *CCL5*, *ISG15* and *IL12B* were more strongly induced by LPS in DAA-cured tissue, previously not identified with HCV-infected tissue (**Fig. 6B**).

In terms of the $\Delta\Delta C_t$ net increase, *TNF*, *CTGF*, *IL-10*, *CX3CL1* were more strongly induced by both polyI:C and LPS in both HCV-infected and DAA-cured liver tissue. *IL-1B* and *IL-8* in HCV-infected, and *IFIT2* in DAA-cured liver tissue were more responsive to LPS (**Fig. 6B**). Importantly, a subset of these genes *TNF*, *CX3CR1* in KC, *CTGF* in LSEC, *CCL7*, *ISG15* for HSC, and *IL-8*, *IL-1B*, *RSAD2*, *CXCL9*, *CCL3* for NPCs were only revealed through the TLR3 and TLR4 stimulation assays, but not with the *ex vivo* day 0 measurements. These results highlighted the unique value to measure dynamic changes with liver tissue to reveal immune signaling defects (**Fig. 6B**).

Discussion

In this study, we pioneered the PCLS technology to study innate immune response with the normal and pathological liver tissue. We showed that immune abnormalities persist after the elimination of HCV by anti-viral therapy, and the persisting inflammatory and immune signatures mapped to hepatic non-parenchymal cells. Innate immunity was not suppressed but enhanced in HCV-infected tissue, and these abnormalities were not corrected after effective DAA treatment.

In human hepatocyte cultures^{51,52} HCV infection triggered cleavage of MAVS and TRIF host proteins by HCV NS3/4A protease, disrupting TLR3-antiviral signaling. Reduction of protein levels of MAVS and TRIF was also observed previously in chronic HCV-infected livers^{53,54}. Nevertheless, we observed a robust response to TLR3 signaling in the HCV-infected liver, which supports the idea that ISG induction is weak in HCV infected cells, but strong in HCV infected liver due to paracrine activation of NPC. The data on the direct effect of HCV on the TLR3 response in liver tissue are novel and distinct from previous work focused on the IFN-induced gene expression in chronically HCV-infected liver by pegylated IFN therapy^{55,56}, since such direct activation of IFN signaling bypasses MAVS and TRIF.

A previous study reported that HBV does not interfere with innate immune response based on chronic HBV-infected liver biopsy tissues⁵⁷. However, in chronic HCV-infected tissue, we found innate immunity to TLR3 and TLR4 was not suppressed but enhanced. The different outcome may reflect the differences in immune evasion mechanisms between DNA and RNA

viruses. Furthermore, the tissue status and treatment method were not identical between two studies. In chronic HCV-infected tissue, advanced fibrosis was observed, and this study also used the day 7 as treatment time zero when immune activation by tissue slicing was broadly stabilized.

From the days of IFN-based therapy, we know that HCV-induced liver disease can regress when the virus is eradicated from the liver⁵⁸. However, halting or reversing liver disease upon IFN cure of HCV has not been universal; some patients with advanced disease still go on to develop HCC⁵⁹⁻⁶¹. DAA drugs are now able to cure the majority of HCV infections, even in subjects with advanced liver disease. Nevertheless, clearance of HCV with DAA treatment may only partially restore immune cell function. In this study, we have identified immune genes that were restored to normal by DAA treatment, and more importantly immune genes that were not restored *ex vivo* (*i.e.*, at day 0 time point), including a subset of immune activation genes, inflammation genes, immune suppression, and PI3K pathway genes.

The era during which some, but not all HCV patients were treated with DAA was brief and has passed. Within this narrow time window, we worked with tissue from patients who were treated for surgical resection of a liver lesion. Accordingly, there are inherent limitations to this study. First, due to the small sample size, we did not further classify patient subgroups based on HCV genotypes. Likewise, other subject characteristics including gender, age, genetic polymorphisms (such as *IL28B*), and liver fibrosis status, all of which may affect immunity and responses to HCV infection^{14,62,63} were not used as factors to subdivide patient groups in the downstream analysis. Surprisingly, we observed significant effects that cut across these hidden variables,

with consistent identification of aberrant immune gene at baseline day 0 and day 7, as well as those with altered TLR3 and TLR4 responses. Second, we cannot determine how far the sustained abnormality is due to the host response to hepatic fibrosis or HCC rather than HCV-mediated. The DAA-cured subjects we studied were based only on those who developed HCC or ICC post DAA therapy, since these were the patients who were subject to liver resection. Thus, our DAA-cured samples only covered a unique sub-group of DAA-cured patients. Future study may extend the conclusion through analysis of a more diverse group of clinical situations, including chronic HCV patients and DAAs-SVR cases with or without fibrosis or HCC, as well as non-HCV related liver tissues with fibrosis or HCC. Liver tissue with longer time span post DAA therapy (>20 months) will also help clarify the resolution of liver cirrhosis by DAA therapy.

We made use of the PCLS approach opportunistically to obtain data from the group of untreated HCV-infected subjects, a group that has now disappeared from the surgical patient pool. While many of the scientific conclusions need to be tentative because of the heterogeneity of both subjects and controls, this study demonstrates the power of PCLS to document functional responses of intact human liver tissue. With appropriate selection of tissue sources, it will add much to the study of human liver immunopathology.

References

- 1 Wu, X. *et al.* Precision-cut human liver slice cultures as an immunological platform. *Journal of immunological methods* **455**, 71-79, doi:10.1016/j.jim.2018.01.012 (2018).

- 2 Kenerson, H. L., Sullivan, K. M., Labadie, K. P., Pillarisetty, V. G. & Yeung, R. S. Protocol for tissue slice cultures from human solid tumors to study therapeutic response. *STAR Protoc* **2**, 100574, doi:10.1016/j.xpro.2021.100574 (2021).
- 3 Polaris Observatory, H. C. V. C. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. *Lancet Gastroenterol Hepatol* **2**, 161-176, doi:10.1016/S2468-1253(16)30181-9 (2017).
- 4 Ringelhan, M., McKeating, J. A. & Protzer, U. Viral hepatitis and liver cancer. *Philos Trans R Soc Lond B Biol Sci* **372**, doi:10.1098/rstb.2016.0274 (2017).
- 5 Zhang, Q. *et al.* HCV core protein inhibits polarization and activity of both M1 and M2 macrophages through the TLR2 signaling pathway. *Sci Rep* **6**, 36160, doi:10.1038/srep36160 (2016).
- 6 Spaan, M. *et al.* Immunological Analysis During Interferon-Free Therapy for Chronic Hepatitis C Virus Infection Reveals Modulation of the Natural Killer Cell Compartment. *J Infect Dis* **213**, 216-223, doi:10.1093/infdis/jiv391 (2016).
- 7 Aregay, A. *et al.* Elimination of Hepatitis C Virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8⁺ T cell responses. *Journal of hepatology*, doi:10.1016/j.jhep.2019.06.025 (2019).
- 8 Najafi Fard, S. *et al.* Direct-acting antiviral therapy enhances total CD4⁺ and CD8⁺ T-cells responses, but does not alter T-cells activation among HCV mono-infected, and HCV/HIV-1 co-infected patients. *Clin Res Hepatol Gastroenterol* **42**, 319-329, doi:10.1016/j.clinre.2017.11.006 (2018).
- 9 Telatin, V. *et al.* In Chronic Hepatitis C Infection, Myeloid-Derived Suppressor Cell Accumulation and T Cell Dysfunctions Revert Partially and Late After Successful Direct-Acting Antiviral Treatment. *Front Cell Infect Microbiol* **9**, 190, doi:10.3389/fcimb.2019.00190 (2019).
- 10 Vranjkovic, A. *et al.* Direct-Acting Antiviral Treatment of HCV Infection Does Not Resolve the Dysfunction of Circulating CD8⁽⁺⁾ T-Cells in Advanced Liver Disease. *Front Immunol* **10**, 1926, doi:10.3389/fimmu.2019.01926 (2019).
- 11 Ghosh, A. *et al.* Persistent gamma delta T-cell dysfunction in chronic HCV infection despite direct-acting antiviral therapy induced cure. *Journal of viral hepatitis* **26**, 1105-1116, doi:10.1111/jvh.13121 (2019).
- 12 Hengst, J. *et al.* Nonreversible MAIT cell-dysfunction in chronic hepatitis C virus infection despite successful interferon-free therapy. *Eur J Immunol* **46**, 2204-2210, doi:10.1002/eji.201646447 (2016).
- 13 Reig, M. *et al.* Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. *Journal of hepatology* **65**, 719-726, doi:10.1016/j.jhep.2016.04.008 (2016).
- 14 Conti, F. *et al.* Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. *Journal of hepatology* **65**, 727-733, doi:10.1016/j.jhep.2016.06.015 (2016).
- 15 Kuftinec, G. *et al.* De novo hepatocellular carcinoma occurrence in hepatitis C cirrhotics treated with direct-acting antiviral agents. *Hepat Oncol* **5**, HEP06, doi:10.2217/hep-2018-0003 (2018).
- 16 Dong Ji, e. a. Increase in Incidence of Hepatocellular Carcinoma in Chronic Hepatitis C Chinese After Sustained Virologic Response with Direct Acting Antiviral Agents as

- 575 Compared to Pegylated Interferon Plus Ribavirin Therapy: A Prospective Open-
576 Label Study. *Preprint with THE LANCET preprint* (2019).
- 577 17 Gitto, S. *et al.* Worsening of Serum Lipid Profile after Direct Acting Antiviral
578 Treatment. *Ann Hepatol* **17**, 64-75, doi:10.5604/01.3001.0010.7536 (2018).
- 579 18 Hamdane, N. *et al.* HCV-Induced Epigenetic Changes Associated With Liver Cancer
580 Risk Persist After Sustained Virologic Response. *Gastroenterology* **156**, 2313-2329
581 e2317, doi:10.1053/j.gastro.2019.02.038 (2019).
- 582 19 Perez, S. *et al.* Hepatitis C virus leaves an epigenetic signature post cure of infection
583 by direct-acting antivirals. *PLoS Genet* **15**, e1008181,
584 doi:10.1371/journal.pgen.1008181 (2019).
- 585 20 Whitcomb, E. *et al.* Biopsy Specimens From Allograft Liver Contain Histologic
586 Features of Hepatitis C Virus Infection After Virus Eradication. *Clin Gastroenterol*
587 *Hepatol* **15**, 1279-1285, doi:10.1016/j.cgh.2017.04.041 (2017).
- 588 21 Bhogal, R. H. *et al.* Isolation of primary human hepatocytes from normal and
589 diseased liver tissue: a one hundred liver experience. *PloS one* **6**, e18222,
590 doi:10.1371/journal.pone.0018222 (2011).
- 591 22 Mohar, I., Brempelis, K. J., Murray, S. A., Ebrahimkhani, M. R. & Crispe, I. N. Isolation
592 of Non-parenchymal Cells from the Mouse Liver. *Methods in molecular biology* **1325**,
593 3-17, doi:10.1007/978-1-4939-2815-6_1 (2015).
- 594 23 Alabraba, E. B. *et al.* A new approach to isolation and culture of human Kupffer cells.
595 *Journal of immunological methods* **326**, 139-144, doi:10.1016/j.jim.2007.06.014
596 (2007).
- 597 24 Ikarashi, M. *et al.* Distinct development and functions of resident and recruited liver
598 Kupffer cells/macrophages. *Journal of leukocyte biology* **94**, 1325-1336,
599 doi:10.1189/jlb.0313144 (2013).
- 600 25 Elvevold, K., Smedsrod, B. & Martinez, I. The liver sinusoidal endothelial cell: a cell
601 type of controversial and confusing identity. *American journal of physiology.*
602 *Gastrointestinal and liver physiology* **294**, G391-400, doi:10.1152/ajpgi.00167.2007
603 (2008).
- 604 26 Buhring, H. J. *et al.* Novel markers for the prospective isolation of human MSC.
605 *Annals of the New York Academy of Sciences* **1106**, 262-271,
606 doi:10.1196/annals.1392.000 (2007).
- 607 27 D'Ambrosio, D. N. *et al.* Distinct populations of hepatic stellate cells in the mouse
608 liver have different capacities for retinoid and lipid storage. *PloS one* **6**, e24993,
609 doi:10.1371/journal.pone.0024993 (2011).
- 610 28 Brempelis, K. J., Yuen, S. Y., Schwarz, N., Mohar, I. & Crispe, I. N. Central role of the
611 TIR-domain-containing adaptor-inducing interferon-beta (TRIF) adaptor protein in
612 murine sterile liver injury. *Hepatology* **65**, 1336-1351, doi:10.1002/hep.29078
613 (2017).
- 614 29 Jang, J. S. *et al.* Quantitative miRNA expression analysis using fluidigm microfluidics
615 dynamic arrays. *BMC genomics* **12**, 144, doi:10.1186/1471-2164-12-144 (2011).
- 616 30 Eisen, M. B., Spellman, P. T., Brown, P. O. & Botstein, D. Cluster analysis and display
617 of genome-wide expression patterns. *Proceedings of the National Academy of*
618 *Sciences of the United States of America* **95**, 14863-14868 (1998).
- 619 31 Saldanha, A. J. Java Treeview--extensible visualization of microarray data.
620 *Bioinformatics* **20**, 3246-3248, doi:10.1093/bioinformatics/bth349 (2004).

- 621 32 Elmasry, S. *et al.* Detection of Occult Hepatitis C Virus Infection in Patients Who
622 Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents for
623 Recurrent Infection After Liver Transplantation. *Gastroenterology* **152**, 550-553
624 e558, doi:10.1053/j.gastro.2016.11.002 (2017).
- 625 33 MacParland, S. A. *et al.* Single cell RNA sequencing of human liver reveals distinct
626 intrahepatic macrophage populations. *Nat Commun* **9**, 4383, doi:10.1038/s41467-
627 018-06318-7 (2018).
- 628 34 Aizarani, N. *et al.* A human liver cell atlas reveals heterogeneity and epithelial
629 progenitors. *Nature* **572**, 199-204, doi:10.1038/s41586-019-1373-2 (2019).
- 630 35 Tu, Z. *et al.* TLR-dependent cross talk between human Kupffer cells and NK cells. *The*
631 *Journal of experimental medicine* **205**, 233-244, doi:10.1084/jem.20072195 (2008).
- 632 36 Armstrong, R. A. When to use the Bonferroni correction. *Ophthalmic Physiol Opt* **34**,
633 502-508, doi:10.1111/opo.12131 (2014).
- 634 37 Lagaye, S. *et al.* Efficient replication of primary or culture hepatitis C virus isolates in
635 human liver slices: A relevant ex vivo model of liver infection. *Hepatology* **56**, 861-
636 872, doi:10.1002/hep.25738 (2012).
- 637 38 Dolmazashvili, E. *et al.* Regression of liver fibrosis over a 24-week period after
638 completing direct-acting antiviral therapy in patients with chronic hepatitis C
639 receiving care within the national hepatitis C elimination program in Georgia:
640 results of hepatology clinic HEPA experience. *European journal of gastroenterology*
641 *& hepatology* **29**, 1223-1230, doi:10.1097/MEG.0000000000000964 (2017).
- 642 39 Hsu, W. F. *et al.* Rapid decline of noninvasive fibrosis index values in patients with
643 hepatitis C receiving treatment with direct-acting antiviral agents. *BMC*
644 *gastroenterology* **19**, 63, doi:10.1186/s12876-019-0973-5 (2019).
- 645 40 Mittal, S. *et al.* Hepatocellular Carcinoma in the Absence of Cirrhosis in United States
646 Veterans is Associated With Nonalcoholic Fatty Liver Disease. *Clin Gastroenterol*
647 *Hepatol* **14**, 124-131 e121, doi:10.1016/j.cgh.2015.07.019 (2016).
- 648 41 Negash, A. A. *et al.* IL-1 β production through the NLRP3 inflammasome by
649 hepatic macrophages links hepatitis C virus infection with liver inflammation and
650 disease. *PLoS Pathog* **9**, e1003330, doi:10.1371/journal.ppat.1003330 (2013).
- 651 42 Lau, D. T. *et al.* Interferon regulatory factor-3 activation, hepatic interferon-
652 stimulated gene expression, and immune cell infiltration in hepatitis C virus
653 patients. *Hepatology* **47**, 799-809, doi:10.1002/hep.22076 (2008).
- 654 43 Brownell, J. *et al.* Independent, parallel pathways to CXCL10 induction in HCV-
655 infected hepatocytes. *Journal of hepatology* **59**, 701-708,
656 doi:10.1016/j.jhep.2013.06.001 (2013).
- 657 44 Brownell, J. *et al.* Direct, interferon-independent activation of the CXCL10 promoter
658 by NF- κ B and interferon regulatory factor 3 during hepatitis C virus infection. *J*
659 *Virol* **88**, 1582-1590, doi:10.1128/JVI.02007-13 (2014).
- 660 45 Meissner, E. G. *et al.* Endogenous intrahepatic IFNs and association with IFN-free
661 HCV treatment outcome. *The Journal of clinical investigation* **124**, 3352-3363,
662 doi:10.1172/JCI75938 (2014).
- 663 46 Wang, L. *et al.* Neuropilin-1 aggravates liver cirrhosis by promoting angiogenesis via
664 VEGFR2-dependent PI3K/Akt pathway in hepatic sinusoidal endothelial cells.
665 *EBioMedicine* **43**, 525-536, doi:10.1016/j.ebiom.2019.04.050 (2019).

- 47 Cai, C. X. *et al.* Activation of Insulin-PI3K/Akt-p70S6K Pathway in Hepatic Stellate Cells Contributes to Fibrosis in Nonalcoholic Steatohepatitis. *Digestive diseases and sciences* **62**, 968-978, doi:10.1007/s10620-017-4470-9 (2017).
- 48 Wu, X. *et al.* Human Liver Macrophage Subsets Defined by CD32. *Front Immunol* **11**, 2108, doi:10.3389/fimmu.2020.02108 (2020).
- 49 Dreux, M. *et al.* Short-range exosomal transfer of viral RNA from infected cells to plasmacytoid dendritic cells triggers innate immunity. *Cell Host Microbe* **12**, 558-570, doi:10.1016/j.chom.2012.08.010 (2012).
- 50 Wieland, S. *et al.* Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver. *Hepatology* **59**, 2121-2130, doi:10.1002/hep.26770 (2014).
- 51 Loo, Y. M. *et al.* Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. *Proc Natl Acad Sci U S A* **103**, 6001-6006, doi:10.1073/pnas.0601523103 (2006).
- 52 Li, K. *et al.* Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. *Proc Natl Acad Sci U S A* **102**, 2992-2997, doi:10.1073/pnas.0408824102 (2005).
- 53 Bellecave, P. *et al.* Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system. *Hepatology* **51**, 1127-1136, doi:10.1002/hep.23426 (2010).
- 54 Kar, P., Kumar, D., Gumma, P. K., Chowdhury, S. J. & Karra, V. K. Down regulation of TRIF, TLR3, and MAVS in HCV infected liver correlates with the outcome of infection. *J Med Virol* **89**, 2165-2172, doi:10.1002/jmv.24849 (2017).
- 55 Sarasin-Filipowicz, M. *et al.* Interferon signaling and treatment outcome in chronic hepatitis C. *Proc Natl Acad Sci U S A* **105**, 7034-7039, doi:10.1073/pnas.0707882105 (2008).
- 56 McGilvray, I. *et al.* Hepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotype. *Gastroenterology* **142**, 1122-1131 e1121, doi:10.1053/j.gastro.2012.01.028 (2012).
- 57 Suslov, A., Boldanova, T., Wang, X., Wieland, S. & Heim, M. H. Hepatitis B Virus Does Not Interfere With Innate Immune Responses in the Human Liver. *Gastroenterology* **154**, 1778-1790, doi:10.1053/j.gastro.2018.01.034 (2018).
- 58 D'Ambrosio, R. & Colombo, M. Should surveillance for liver cancer be modified in hepatitis C patients after treatment-related cirrhosis regression? *Liver international : official journal of the International Association for the Study of the Liver* **36**, 783-790, doi:10.1111/liv.13106 (2016).
- 59 Makiyama, A. *et al.* Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. *Cancer* **101**, 1616-1622, doi:10.1002/cncr.20537 (2004).
- 60 van der Meer, A. J. *et al.* Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. *Journal of hepatology* **66**, 485-493, doi:10.1016/j.jhep.2016.10.017 (2017).
- 61 van der Meer, A. J. *et al.* Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. *JAMA* **308**, 2584-2593, doi:10.1001/jama.2012.144878 (2012).

- 712 62 Schott, E. *et al.* Gender-dependent association of CTLA4 polymorphisms with
 713 resolution of hepatitis C virus infection. *Journal of hepatology* **46**, 372-380,
 714 doi:10.1016/j.jhep.2006.09.011 (2007).
 715 63 Yan, Z. & Wang, Y. Viral and host factors associated with outcomes of hepatitis C
 716 virus infection (Review). *Mol Med Rep* **15**, 2909-2924, doi:10.3892/mmr.2017.6351
 717 (2017).
 718

719

720 **Figure legends**

721 **See figures**

722

723

724 **Table**

725

Table 1 Immune gene changes *ex vivo* (Day 0)

	Fold change			Statistical significance ²			Cell-type-specific information ³
	¹ HCV/ Con	DAA/ Con	DAA/ HCV	HCV/ Con	DAA/ Con	DAA/ HCV	
Antiviral genes							
Cured by DAA at D0 baseline ⁴							
CXCL10	54.39	2.93	0.05	0.0003	0.4598	0.0004	NPC, KC
RSAD2	7.68	1.05	0.14	0.0007	0.7197	0.0007	NPC
IFIT1	7.16	1.51	0.21	0.0007	0.211	0.002	NPC
IFIT3	7.02	1.61	0.23	0.0002	0.0653	0.0004	NPC
CXCL9	6.80	1.45	0.21	0.0016	0.7197	0.0017	NPC, HSC
IFIT2	5.39	1.82	0.34	0.0007	0.0535	0.033	NPC, HSC
ISG15	6.16	1.04	0.17	0.0115	0.8421	0.0012	likely NPC, HSC
MX1	7.05	1.01	0.14	0.0004	0.9682	0.0002	likely NPC
Immune activation genes							
NOT cured by DAA at D0 baseline ⁵							
HLA-A	3.84	1.61	0.42	0.0002	0.022	0.0012	NPC, LSEC
CCL5	3.30	1.92	0.58	0.0033	0.022	0.0878	NPC
CCR2	9.93	4.45	0.45	0.0007	0.0104	0.02	likely NPC
4-1BB (CD137, TNFRSF9)	6.35	3.17	0.50	0.0007	0.0279	0.0702	likely NPC
CIITA	5.03	4.64	0.92	0.0007	0.0003	0.6691	likely KC
Cured by DAA at D0 baseline							
HLA-DRA	2.53	1.43	0.56	0.0052	0.2775	0.1088	NPC
CD80	3.54	1.91	0.54	0.0012	0.1823	0.0553	NPC
CD86	2.32	1.25	0.54	0.0418	0.447	0.1613	NPC
OX40 (TNFRSF4)	3.93	2.46	0.63	0.0033	0.0789	0.3638	LSEC
TNFRSF18	5.62	2.97	0.53	0.0006	0.0745	0.351	HSC, LSEC
TNFSF9	2.97	2.08	0.70	0.036	0.2224	0.2721	likely KC
CXCL1	2.73	1.01	0.37	0.1447	0.9048	0.003	HSC
IFNG	2.69	0.83	0.31	0.1738	>0.9999	0.0431	NPC
Inflammation genes							
NOT cured by DAA at D0 baseline							
CASP1	3.13	2.71	0.87	0.0007	0.0435	0.0136	NPC
IL-12A	3.71	1.91	0.51	0.0037	0.0434	0.0185	LSEC

Cured by DAA at D0 baseline							
IL-12B	2.86	1.29	0.45	0.0262	0.7577	0.1738	HSC
TNF	2.77	1.06	0.38	0.0115	0.7802	0.0046	NPC, KC, HSC
IL-18	2.40	0.90	0.37	0.0164	0.6607	0.025	NPC, HSC
NFKB	1.46	1.01	0.69	0.0283	>0.9999	0.0317	N/A
Immune Suppression genes							
NOT cured by DAA at D0 baseline							
CTLA4	6.52	2.70	0.41	0.0003	0.0172	0.033	likely NPC
TIGIT	4.77	3.20	0.67	0.0003	0.0172	0.033	likely NPC
IDO1	4.35	2.52	0.58	0.0052	0.0435	0.1613	NPC
ARG1	0.45	0.39	0.89	0.0229	0.0056	0.6806	Hep, uncommon in KC, LSEC
Cured by DAA at D0 baseline							
B7-H4	4.49	3.70	0.83	0.0059	0.0541	0.7104	HSC
VISTA (VSIR)	2.10	1.40	0.67	0.0021	0.1333	0.3638	KC, LSEC, HSC
CD47	1.43	1.24	0.87	0.0418	0.3562	0.3148	NPC, KC, LSEC, HSC
PDCD1	5.16	2.30	0.44	0.0205	0.0592	0.1416	not cell-type-specific
LAG3	1.88	1.19	0.64	0.0164	>0.9999	0.0712	not cell-type-specific
TIM3	2.18	0.99	0.46	0.0079	0.8633	0.0164	NPC
FOXP3	2.94	0.70	0.24	0.1416	0.8633	0.0079	not cell-type-specific
PI3K pathway genes							
NOT cured by DAA at D0 baseline							
SPHK1	3.50	2.13	0.61	0.0052	0.04	0.2523	HSC
BTG2	2.19	2.10	0.96	0.0907	0.0188	0.8371	N/A
SOX9	2.62	2.30	0.88	0.0549	0.04	>0.9999	Not cell-type-specific
SNAP25	3.03	1.88	0.62	0.0164	0.0503	0.351	N/A
GPRC5B	2.30	1.91	0.83	0.0311	0.1615	0.351	N/A
Tissue repair genes							
Cured by DAA at D0 baseline							
TIMP1	1.98	1.29	0.65	0.0311	0.447	0.2698	LSEC
MMP9	2.04	1.13	0.56	0.0164	0.7802	0.1331	Not cell-type-specific
PDGFB	1.62	0.93	0.58	0.2523	0.8633	0.0164	LSEC
TGFB1	2.18	1.27	0.58	0.0712	0.447	0.0431	KC, LSEC, HSC

Liver tissue was perfused, and total livers, hepatocytes (Hep) and NPC populations (NPC) were obtained with differential centrifugation. Kupffer cells (KC), liver sinusoidal endothelial cells (LSEC), and hepatic stellate cells (HSC) enriched populations were obtained with FACS from NPC (Fig. 1B). RNA was extracted from each cell type, followed by qRT-PCR gene expression analysis using the fluidigm platform.

¹The comparisons were HCV/ Con, chronic HCV-infected versus non-infected controls; DAA/ Con, DAA-cured versus non-infected controls; DAA/HCV, DAA-cured versus chronic HCV-infected.

²Statistical significance was based on non-parametric two-tailed Mann-Whitney test.

³Cell-type-specific information was based on analysis of the non-HCV-infected samples. N/A means cell-type-specific gene information not analyzed. This was due to the limit of sample availability and the assay through-put with fluidigm assays.

⁴Cured by DAA at D0 baseline categorized the gene subsets that were normalized to the same level as non-infected controls.

⁵Not cured by DAA at D0 baseline categorized gene subsets that were not normalized to the correct levels as the non-infected controls.

Figure 1

Figure 1. Innate immune response of human liver slices to polyI:C or LPS treatment. Non-HCV-infected specimens are shown. IFN-β, IFN-γ and IFN-λ expression peaked at 2-4 h, whereas interferon-stimulated gene expression for IFIT1, MX1 and CXCL10 peak round 4-12 h. Each marker represents a patient time-point summary which consist of 2-3 biological replicates of liver slices. Relative abundance at the log2 scale is shown, with the median, 25% and 75% quantile values indicated with violin plots.

Figure 2

Figure 2. HCV and fibrosis analysis with human liver slices. (A) All eight chronic HCV samples (blue color) were confirmed with positive HCV RNA detection. None of the DAA cured subjects (red color) or the non-infected controls (black color) was positive for HCV RNA. n.d., meaning non-detected. The limit of reliable detection (LoD) was 1.2 IU/50 ng liver total RNA. (B) HCV RNA remained robustly detected in the day 7 liver slices cultured from chronically HCV-infected patients. The viral load between day 0 and day 7 liver slices was not statistically significant ($P=0.4688$, Wilcoxon matched-pairs signed rank test). (C) Fibrosis analysis of the day 0 ex vivo liver specimens with trichrome staining and picosirius red staining indicated that in DAA-treated, and now HCV-negative patients in this study there was persistent fibrosis, similar to untreated HCV and different from tissue without a history of HCV infection. The scoring system was based on the Scheuer/Batts-Ludwig method. Data included 10 non-infected patients, 4 chronic HCV patients, and 8 DAA-treated patients, with the minimum and maximum data points for each subgroup being shown. Statistical significance was based on Mann-Whitney test. **, $P < 0.01$. ††, $P < 0.01$

Figure 3

DAA-4

Fibrosis score: 4

DAA-9

Fibrosis score: 4

Chronic HCV

Fibrosis score: 4

Non-infected

Fibrosis score: 0

Figure 3. Examples of trichrome stain, picrosirius red stain, and H&E stain analysis of human liver slices. Arrow indicates the nodule formation in the cirrhosis livers. The Scheuer/Batts-Ludwig method was used for fibrosis scoring, with 0: No fibrosis, 1: portal fibrosis, 2: peri-portal fibrosis, 3: bridging fibrosis, and 4: cirrhosis. The DAA-4 liver tissue was collected 12 months after the completion of 24-week DAA therapy, DAA-9 liver tissue was collected 20 months after the completion of 12-week DAA therapy.

Figure 4

A

B

Figure 4. Immune gene changes at the day 7 baseline in chronic HCV-infected and DAA-cured livers. (A) Hierarchical clustering of immune genes with statistically significant elevation in HCV or DAA-cured subjects at Day 0 or Day 7 time points. The group-level fold changes are shown, which were calculated with the mean Ct value of each gene within each patient group. Decreased fold changes are colored in green, and increased fold changes are colored in red. (B) The up-regulated genes in HCV and DAA-cured at day 7 time points. Genes were mapped to liver cell types according to the cell type analysis with day 0 non-infected livers. Genes are grouped by expression patterns in cell compartments and in specimens type. The overlapped genes up-regulated at both day 0 and day 7 time points are bolded and underscored.

Figure 5

Figure 5. Delta-delta Ct analysis showing up-regulated genes post- poly-I:C or LPS stimulation in chronic HCV-infected and DAA-cured liver slices. The relative gene abundance was normalized to the arithmetic mean of Ct values of ACTB, GAPDH and HPRT1. The relative abundance was further normalized to the day 7 time zero measurements. Statistical significance was based on two-tailed Mann-Whitney test. *, statistical significantly different between non-infected versus chronic HCV liver slices. †, statistical significantly different between non-infected versus DAA-cured liver slices. ‡, statistical significantly different between chronic HCV versus DAA-cured liver slices. Levels of statistical significance *, P <0.05 **, P<0.01, ***, P<0.001. The mean and standard deviation within each group are plotted.

Figure 6

Figure 6. Altered TLR3 and TLR4 response in chronic HCV-infected liver slices not restored in DAA-cured liver slices. (A) Hierarchical clustering of immune responsive genes with 2-fold or greater induction during LPS stimulation. The statistical significance P value with ΔCt method is shown. Gene abundance of individual liver slices was normalized to the arithmetic mean of Ct values of ACTB, GAPDH and HPRT. Two-tailed Mann-Whitney test was used. Greater significance P value is colored with darker red. (B) Immune genes up-regulated in polyI:C or LPS treatment were mapped to live cell compartment according to the day 0 information. Genes identified with $\Delta\Delta Ct$ method, i.e. with an enhanced net increase during TLR3/TLR4 response is highlighted with a black bordering. Genes elevated in HCV- or DAA- samples or both are colored accordingly. Elevated genes were grouped by whether they were differentially expressed in TLR3 or TLR4 treatment not at the baseline level, and whether polyI:C or LPS treatment revealed differential responses. Antiviral genes RSAD2, CXCL9, MX1, IFIT3 were corrected at baseline in DAA-cured samples, but manifested abnormal up-regulation during polyI:C and LPS treatment.